Statements (61)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:activities |
vasodilator
|
gptkbp:approves |
gptkb:2002
|
gptkbp:brand |
gptkb:Remodulin
|
gptkbp:class |
prostacyclin analog
|
gptkbp:clinical_trial |
studied in multiple clinical trials
chronic treatment |
gptkbp:contraindication |
severe hepatic impairment
hypersensitivity to treprostinil |
gptkbp:dosage_form |
solution for injection
|
gptkbp:duration |
long-term therapy
|
gptkbp:education |
storage instructions
recognizing side effects importance of adherence proper injection technique when to seek medical help |
gptkbp:effective_date |
FDA approved
|
gptkbp:formulation |
sterile solution
|
gptkbp:frequency |
continuous infusion
subcutaneous infusion every 24 hours |
https://www.w3.org/2000/01/rdf-schema#label |
Remodulin
|
gptkbp:indication |
improving exercise ability
|
gptkbp:ingredients |
C20 H30 O5 S
treprostinil |
gptkbp:interacts_with |
anticoagulants
antihypertensives other vasodilators |
gptkbp:is_available_on |
generic version
|
gptkbp:is_monitored_by |
blood pressure
heart rate symptoms of pulmonary hypertension |
gptkbp:is_used_for |
pulmonary arterial hypertension
|
gptkbp:lifespan |
approximately 4 hours
|
gptkbp:manager |
intravenous infusion
subcutaneous injection |
gptkbp:manufacturer |
gptkb:United_Therapeutics_Corporation
|
gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
gptkbp:packaging |
vials
|
gptkbp:pharmacokinetics |
metabolized in the liver
increases blood flow |
gptkbp:population |
adults and children
|
gptkbp:safety_features |
generally well tolerated
|
gptkbp:side_effect |
gptkb:fandom
dizziness headache nausea vomiting diarrhea thrombocytopenia hypotension palpitations jaw pain flushing injection site reaction |
gptkbp:storage |
refrigerated
|
gptkbp:type_of_care |
important for efficacy
|
gptkbp:bfsParent |
gptkb:Treprostinil
gptkb:United_Therapeutics_Corporation |
gptkbp:bfsLayer |
6
|